HER-2 positive locally recurrent or metastatic breast cancer MedDRA version: 9.1 Level: LLT Classification code 10065430 Term: HER-2 positive breast cancer
Conditions
Interventions
Product Name: Panobinostat
Product Code: LBH589A
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Panobinostat
CAS Number: 404950-80-7
Current Sponsor code: LBH589
Concentration unit:
Sponsors
Cancer International Research Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Women = 18 years old • Patients with an ECOG performance status of = 2 assessed within 2 weeks (14 days) prior to randomization • Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent. • Measurable disease per RECIST guidelines • HER2-positive breast cancer patients by local laboratory testing (IHC 3+ staining or in situ hybridization positive). • Prior trastuzumab-containing regimen (in neoadjuvant and/or adjuvant and/or metastatic settings) regardless of whether trastuzumab was given as monotherapy or in combination with chemotherapy. Any number of prior trastuzumab regimens is acceptable. Additional treatment with lapatinib after or before trastuzumab treatment is permitted, but not mandatory. • Radiological evidence of relapse or disease progression while on trastuzumab (or lapatinib) or within 12 months of the last dose of adjuvant trastuzumab. • Complete radiology and tumor assessment within 4 weeks (28 days) prior to randomization: ? Chest: CT scan with intravenous contrast if the contrast is not medically contraindicated or MRI ? Abdomen: CT scan with intravenous and oral contrast if the contrast is not medically contraindicated or MRI ? Brain: CT scan or MRI ? Bone: Whole body Bone Scintigraphy • Up to 2 prior cytotoxic chemotherapy regimens, in addition to neo-adjuvant and adjuvant, for treatment of metastatic or locally recurrent breast cancer (including those cyctotoxic chemotherapy treatments in combination with trastuzumab and/or lapatinib) • Patients must meet the following laboratory criteria within 2 weeks (14 days) prior to randomization: • Hematology • Neutrophil count of > 1200/mm3 • Platelet count of > 100,000/mm3 • Hemoglobin = 90 g/L • Biochemistry • AST/SGOT and ALT/SGPT = 2.5 x upper limit of normal (ULN) or = 5.0 x ULN if the transaminase elevation is due to disease involvement • Serum bilirubin = 1.5 x ULN • Serum creatinine = 1.5 x ULN or 24-hour creatinine clearance = 50 mL/min • Serum potassium, sodium, magnesium, phosphorus, total calcium (corrected for serum albumin) or ionized calcium within normal limits for the institution • Serum albumin = LLN or 30g/L • Clinically euthyroid function (TSH and free T4). (Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism). • LVEF assessment (2-D echocardiogram or MUGA scan) performed within 6 weeks prior to randomization, showing a LVEF value > 50% • Electrocardiogram performed within 1 week prior to randomization (details about findings on the Electrocardiogram that are not acceptable for participating in the study are reported in the Exclusion criteria section) • Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization and agree to appropriate method of pregnancy prevention Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer • Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first panobinostat treatment • Patients who have received prior chemotherapy or investigational agent within the last 4 weeks prior to randomization (6 weeks for nitrosoureas and mitomycin; 2 weeks for capecitabine) • Patients who have received prior radiotherapy to = 25% of the bone marrow within the last 4 weeks prior to randomization; local radiotherapy is allowed however all recently irradiated lesions should not be included in the measurable disease assessment • Patients who have received prior investigational agents within the last 4 weeks prior to randomization • Patients with unresolved diarrhea =CTCAE grade 1 • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat • History of cardiac dysfunction including any one of the following: • Complete left bundle branch block or necessasity for a permanent cardiac pacemaker or congenital long QT syndrome or history or presence of ventricular tachyarrhythmias or clinically significant resting bradycardia ( 450 msec on screening ECG or right bundle branch block and left anterior hemiblock (bifasicular block) • Presence of unstable atrial fibrillation (ventricular response rate >100 bpm). Patients with stable atrial fibrillation are allowed in the study provided they do not meet the other cardiac exclusion criteria • Previous history angina pectoris or acute MI within 6 months of randomization • Congestive heart failure (New York Heart Association functional classification III-IV) • Other clinically significant heart disease (e.g. cardiomyopathy, cardiac artery disease, uncontrolled hypertension, or history of poor compliance with an antihypertensive regimen) • Acute or chronic liver or renal disease • Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes mellitus, active untreated or uncontrolled infection, chronic obstructive or chronic restrictive pulmonary disease including dyspnoea at rest from any cause) that could cause unacceptable safety risks or compromise compliance with the protocol • Concomitant use of drugs with a risk of causing torsades de pointes where such treatments cannot be discontinued or switched to a different medication prior to starting study drug • Brain metastases, unless patient randomized on study at least 90 days from completion of brain radiotherapy and / or surgery without radiologic or functional evidence of progressive brain metastases, and off corticosteroids above the dose of 7.5 mg prednisone or equivalent; No concurrent radiotherapy for brain metastasis is allowed • Clinically significant third space fluid accumulation • Concurrent bisphosphonates unless if initiated prior to study entry (at least 4 weeks before study randomization) • Pregnant (i.e., positive beta-human chorionic gonadotropin test) or breast feeding • Unable to swallow oral medications • Not willing to use a double barrier method of non-hormonal birth control. Contraception must be used during the study and for 90 days after last dose of study treatment. • Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To assess the effect (objective response rate) of i.v. and oral panobinostat monotherapy using RECIST criteria as per investigator assessment.;Secondary Objective: • To assess the effect (objective response rate) of i.v. and oral panobinostat monotherapy as per independent central review • To assess the progression-free survival, the time to response, the duration of response, the disease control rate and the overall survival of i.v. and oral panobiostat monotherapy • To evaluate the safety and tolerability profile of i.v. and oral panobinostat monotherapy, with careful monitoring of the QTcF interval. ;Primary end point(s): Objective response rate (as determined by the investigator): the percentage of patients assigned to a treatment arm with a confirmed best response of CR or PR. | — |
Countries
Belgium, France, United Kingdom
Outcome results
None listed